Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vor Biopharma Inc. filings document a clinical-stage biotechnology issuer focused on telitacicept and autoimmune disease development. The record includes Form 8-K disclosures for operating and financial results, Regulation FD presentations, clinical and regulatory updates, material agreements, governance changes and capital-structure matters.
Proxy materials describe director elections, equity incentive plan matters, auditor ratification and annual-meeting voting procedures. Other filings address executive compensation arrangements, Nasdaq-listed common stock, a reverse stock split, equity plan share adjustments and security-holder rights tied to the company’s common stock and outstanding awards.
Vor Biopharma Inc. reported a Form 4 showing a stock option grant related to Dr. Andrew Levin, connected with RA Capital. The option covers 57,162 shares of Vor Biopharma common stock at an exercise price of $14.09 per share, expiring on June 10, 2036. One thirty-sixth of the option vests on July 11, 2026 and then monthly, as long as Dr. Levin continues in service. Under his arrangement with the adviser, the option is held for the benefit of RA Capital Healthcare Fund, and the reporting persons disclaim beneficial ownership except for any pecuniary interest.
Vor Biopharma Inc. director Michel Detheux received a grant of stock options covering 57,162 shares of common stock. The options have an exercise price of $14.09 per share and expire on June 10, 2036. These are compensation-related awards, not open-market purchases.
One thirty-sixth of the option grant will vest and become exercisable on July 11, 2026, with additional installments vesting monthly thereafter, conditioned on Detheux’s continued service. Following this award, he holds options for 57,162 shares directly according to this filing.
Vor Biopharma Inc. director Fouad Namouni received a grant of stock options covering 56,549 shares of common stock. The options have an exercise price of $14.0900 per share and expire on June 10, 2036. One thirty-sixth of the options will vest and become exercisable on July 11, 2026, with additional portions vesting monthly thereafter, contingent on his continued service. Following this grant, he holds 56,549 stock options directly.
Vor Biopharma director Wouter Joustra received a stock option grant covering 57,162 shares of common stock. The option has an exercise price of $14.09 per share and expires on June 10, 2036. One thirty-sixth of the award vests monthly starting July 11, 2026, contingent on continued service. Following this compensation-related grant, Joustra holds 57,162 options directly and there were no open-market buys or sales reported.
Vor Biopharma Inc. director Erez Kalir received a grant of stock options covering 57,162 shares of common stock. The options have an exercise price of $14.09 per share and expire on June 10, 2036. One thirty-sixth of the options vest on July 11, 2026 and then monthly thereafter, subject to continued service, so the award vests over three years. Following this grant, the reported derivative holdings from this award total 57,162 options held directly.
Vor Biopharma Inc. reported that director Alexander Cumbo received a grant of stock options on Common Stock as part of his compensation. The award covers 56,345 options with an exercise price of $14.09 per share, all held directly.
These options expire on June 10, 2036 and relate to 56,345 underlying shares of Common Stock. According to the vesting terms, one thirty-sixth of the options will vest and become exercisable on July 11, 2026 and each month thereafter, conditioned on Mr. Cumbo’s continued service through each vesting date.
Vor Biopharma director Daniella Beckman received a grant of 53,283 stock options to buy Vor Biopharma common stock at an exercise price of $14.09 per share. These options were awarded as compensation and are held directly.
According to the vesting schedule, one thirty-sixth of the options will vest and become exercisable on July 11, 2026, with additional installments vesting monthly thereafter, as long as she continues to serve the company. After this grant, she holds stock options covering 53,283 underlying shares, which will expire on June 10, 2036 if not exercised.
Vor Biopharma Inc. reported that director Andrew David Levin was granted a stock option covering 57,162 shares of common stock at an exercise price of $14.09 per share. The option expires on June 10, 2036 and is a compensation-related award.
One thirty-sixth of the option vests and becomes exercisable each month starting on July 11, 2026, subject to his continued service. Under an arrangement with RA Capital Management, L.P., Levin holds this option for the benefit of the RA Capital Healthcare Fund, L.P. and is obligated to turn over any net cash or stock received, and he therefore disclaims beneficial ownership of the option and underlying shares.
Vor Biopharma Inc. reported results from its 2026 annual stockholder meeting and changes to its equity incentive plan. Stockholders approved an amended and restated 2021 Equity Incentive Plan that keeps the automatic annual share increase but now bases it on both issued and outstanding common shares and shares issuable from pre-funded warrants. The amended plan also provides that, unless an award agreement states otherwise, unvested time-based awards held by an employee will fully vest if the employee’s service ends due to death. Two Class II directors, Andrew Levin and Fouad Namouni, were re-elected, the equity plan amendment was approved, and Ernst & Young LLP was ratified as independent auditor for the year ending December 31, 2026.
Vor Bio reported that its partner RemeGen has received decisions from China’s National Medicinal Products Administration for telitacicept in two autoimmune kidney and rheumatologic diseases. Telitacicept gained conditional approval for treating adult patients with IgA nephropathy and full approval for adult patients with Sjögren’s disease in China.
The IgA nephropathy decision is based on Phase 2 and Phase 3 data, including a 59% reduction in urinary protein-to-creatinine ratio at Week 39 with telitacicept 240 mg and a favorable safety profile. Telitacicept is described as the first and only BAFF/APRIL-targeting therapy approved for IgA nephropathy.
For Sjögren’s disease, a Phase 3 study showed statistically significant improvements in the ESSDAI disease activity score and clinically meaningful gains in the ESSPRI patient-reported index across 160 mg and 80 mg doses with sustained benefit to Week 48. Telitacicept is the first approved therapy for Sjögren’s disease in China. RemeGen controls development and commercialization in China, while Vor Bio holds exclusive rights outside Greater China and is advancing global Phase 3 programs.
Vor Bio reported that its partner RemeGen has received decisions from China’s National Medicinal Products Administration for telitacicept in two autoimmune kidney and rheumatologic diseases. Telitacicept gained conditional approval for treating adult patients with IgA nephropathy and full approval for adult patients with Sjögren’s disease in China.
The IgA nephropathy decision is based on Phase 2 and Phase 3 data, including a 59% reduction in urinary protein-to-creatinine ratio at Week 39 with telitacicept 240 mg and a favorable safety profile. Telitacicept is described as the first and only BAFF/APRIL-targeting therapy approved for IgA nephropathy.
For Sjögren’s disease, a Phase 3 study showed statistically significant improvements in the ESSDAI disease activity score and clinically meaningful gains in the ESSPRI patient-reported index across 160 mg and 80 mg doses with sustained benefit to Week 48. Telitacicept is the first approved therapy for Sjögren’s disease in China. RemeGen controls development and commercialization in China, while Vor Bio holds exclusive rights outside Greater China and is advancing global Phase 3 programs.